Mary Kerr is the founder of NeRRe Therapeutics. NeRRe Therapeutics has raised $43M in total funding. Latest round: Series B. Based in Stevenage, UK.
Mary Kerr is the CEO of NeRRe Therapeutics, a clinical-stage company developing neurokinin receptor antagonists for conditions caused by neuronal hypersensitivity. The company is developing orvepitant for chronic cough and NT-814 for post-menopausal vasomotor symptoms. NeRRe Therapeutics has raised funds in Series B and B2 financing rounds, with investors including Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, Novo A/S, Columbus Venture Partners, and the UK Government’s Future Fund. She was formerly SVP and Global Franchise lead at GSK.
Full founder directory · Investor directory · Company funding database · Fundraising library